• Biomolecules & Therapeutics
• /
• 제8권4호
• /
• pp.318-324
• /
• 2000

We have examined inhibitory erects on gasritis using omeprazole-cholestyramine resinate, which has been developed to increase the stability of omeprazole, the well-known proton pump inhibitor, in an acidic condition. To test the pharmacological action of this, we investigated the effect of omeprazole-cholestyramine resinate on indomethacin-induced gastritis in rats. Omeprazole was used as a reference drug. Orally administered omeprazole-cholestyramine resinate inhibited the indomethacin-induced gastritis in a dose-dependent manner. The inhibitory effect of omeprazole-cholestyramine resinate on the gastritis was similar to that of reference drug. In addition, rectal adminstration of the omeprazole-cholestyramine resinate inhibited the indomethacin-induced gastritis in a dose-dependent manner. The inhibitory effect of omeprazole-cholestyramine resinate was equipotent to reference drug. The basal gastric acid secretion was decreased when it was administered either orally or rectally. This inhibition of omfprazole-cholestyramine resinate was similar to that of omeprazole. These data suggest that omeprazole-cholestyramine resinate inhibit the gastritis in rats, and are comparable to omeprazole available in market.

• Journal of Pharmaceutical Investigation
• /
• 제18권3호
• /
• pp.133-137
• /
• 1988

In vitro studies were performed on the interaction of indomethacin with cholestyramine, a hypocholesterolemic substance. Cholestyramine showed a marked affinity for indomethacin among tested acidic drugs and the intensity of adsorption was dependent on pH, temperature and sodium chloride. Moreover, the combination of indomethacin with some acidic drugs that formed complexes with cholestyramine, considerably inhibited the adsorption of indomethacin on the resin.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
• /
• pp.329-329
• /
• 1994

OMZ과 HP-$\beta$-CD 포접화합물의 유형은 $A_{L}$ type의 가용성 복합체이며, CD, UV, IR, DSC, XRD pattern 및 $^1$H-NMR 방법으로 측정한 포접화합물의 결함형태는 OMZ의 benzimidazole부분이 HP-$\beta$-CD 공동에 포접된 형태이었고, OMZ과 HP-$\beta$-CD의 결합조성몰비는 1:1, 안정도 상수는 약 34 M$^{-1}$이었다. 또한 cholestyramine 수지와 OMZ 복합체는 방출양상이 신속하였다. OMZ-cholestyramine 수지염은 안정성이 양호하고 용출율이 우수한복합체로 경구용 재제를 개발할 수 있었으며, 용출시험 및 산 저항성이 양호하고 pellet의 제조에 있어서 core의 제조는 정제수 : 에탄올(7: 3) 결합액을 이용하여 lactose를 주로 사용하고 기타 PEG 6000, sorbitol, Avicel PH101, sodium lauryl sulfate 및 무수 PVP K-30을 적절히 배합하여 제조하고, 장용코팅의 내산성은 90.5% 이었으며, 소장에서의 용출경향이 85%이상이 10분 이내에 용출되어 규정에 적합하였다.

• Asian-Australasian Journal of Animal Sciences
• /
• 제7권4호
• /
• pp.513-516
• /
• 1994

The effects of the prevention of micelle formation and bile acid reabsorption, by using cholestyramine (CHOLN), a bile acid binding polymer, on the plasma lipid of Single Comb White Leghorn male chicks given diets containing medium chain triacylglycerol (MCT) and long chain triacylglycerol (LCT) were investigated. Corn oil and glyceryl tricaprylate were used as LCT and MCT sources, respectively. Plasma HDL cholesterol was reduced by CHOLN in all treatments. Plasma LDL cholesterol was reduced by CHOLN in chicks given LCT diet but not in MCT diet which could be accounted to the reduced plasma total cholesterol in LCT diet with CHOLN. It is concluded that bile acid binding does not alter the cholesteremic effect of MCT in the plasma of chicks.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1995년도 춘계학술대회
• /
• pp.133-133
• /
• 1995

각종 OMP 복합체들은 OMP에 비해 용해도가 2.7-12.0배 증가하였으며, 모두 10분 이내에 85% 이상이 용출되어 용출규정에 적합하였고 pH 및 습도에 따른 안정성 결과도 OMP에 비해 각종 OMP 복합체가 안정성이 증가되었다. OMP-cholestyramine 수지염의 경우 온도, 습도 및 수용액 중에서의 안정성 모두 OMP에 비하여 향상되었으며, 4$0^{\circ}C$, RH 75%의 가혹조건에서도 OMP pellet에 비해 OMP-cholestyramine 수지염 pellet이 안정성과 내산성이 매우 우수하였다.

• Tuberculosis and Respiratory Diseases
• /
• 제66권6호
• /
• pp.477-481
• /
• 2009

Leflunomide는 항류마티스 약제로 최근 류마티스 관절염 치료에 효과적으로 사용되고 있다. 최근 본 약제로 인한 간질성 폐렴이 일본과 한국에서 서구에서보다 많이 보고되고 있으며 종종 사망하는 경우도 보고되고 있다. 저자들은 25세 여자에서 Methotrexate와 Leflunomide의 병합요법 중 발생한 간질성 폐렴을 진단하였고 Methylprednisolone과 Cholestyramine을 조기 투여하여 효과적으로 치료하였기에 문헌 고찰과 함께 보고하는 바이다.

• 한국식품영양과학회지
• /
• 제23권1호
• /
• pp.23-30
• /
• 1994

This study was carried out to investigate the effect of the feeding mixture of linseed oil, rich in n-3 PUFA and the sunflower seed oil, rich in n-6 PUFA on the lipid metabolism in the dietary hyperlipidemic rats. After male Sprague-Dawley rats were induced hyperlipidemia by feeding the diet containing lard, butter and cholesterol for 3 weeks, then they were fed with the diet containing lard 3.0 % and butter 12.0% for control, the mixture in different proportion of both linseed oil and sunflower seed oil and antihyperlipidemic drugs for 2 weeks. Analysis of the lipid component of the serum showed following results. Concentration of total cholesterol in serum was significantly lower in the other groups except group 2 (lard 3.0 % + olive oil 12.0%) than in the control group , especially in groups 3 (cholestyramine 2.0%) and 5 (lard 3.0% + linseed oil 12.0%). HDL-C and the ratio of HDL-C to total cholesterol concentration were higher in groups 1, 3, 5 and 9 (lard 3.0% + sunflower seed oil 12.0%) , while the atherosclerotic index was low in groups3, 5. Concentrations of free cholesterol and choesteryl ester in serum were significantly lower in the other groups except group 2 than in the control group, especially lower in grop 5. Concentration of LDL was significantly higher in group 2 while it was remarkably lower in groups 3 and 5, while those of triglyceride in groups in 3 and 4 (lipraroid) were significantly higher than in the control groups. From the data on concentration of total choelsterol , HDL-cholesterol, LDL, phospholipid and triglyceride in serum, the results suggested that the feeding mixed with 3.0% lard and 12.0% linseed oil or 2.0% cholestyramine were most effective for the improvement of the serum lipids.

• 한국식품영양과학회지
• /
• 제25권6호
• /
• pp.958-962
• /
• 1996

해조류인 참도박으로 부터 고지혈증 개선효과를 관찰하기 위하여 고지혈증을 유발시킨 흰쥐에 메탄올 추출물을 투여하고 혈액 및 간조직에서의 지방 함량을 측정하였다. 그 결과 참도박의 메탄올 추출물의 투여는 지방조직의 무게는 정상군에는 미치지 않으나 대조군에 비해 다소 감소하는 경향을 보였다. 고지방식이로 인위적으로 고지혈증을 유발시켰을때 정상군보다 total cholesterol, LDL-cholestero의 함량이 증가되던 것이 추출물의 투여로 total cholesterol의 함량이 현저히 감소되었으나 LDL-cholesterolt의 함량은 별다른 영향이 없었다. 또한 이들의 고지방식이군 보다 total lipid, triglyceride의 함량도 감소시켰다.

• 약학회지
• /
• 제42권6호
• /
• pp.572-575
• /
• 1998

Chitosan has been known to have hypocholesterolemic and hypolipidemic effects in animal studies. Chitosan also absorbs bile acids in vitro and in vivo, which might result in the hypocholesterolemic action. Trialkyl chitosan derivatives were prepared and tested for bile acid absorption activity in vitro. The derivatives showed enhanced absorption capacities which were comparable to cholestyramine.

• 보건행정학회지
• /
• 제9권3호
• /
• pp.70-94
• /
• 1999

This paper was performed for a cost-effectiveness analysis of pharmacologic treatment of hypercholesterolemia. Agents modeled were cholestyramine, gemfibrozil. bezafibrate, lovastatin, pravastatin, simvastatin. Pharmacologic effectiveness was estimated by regression from reported clinical trials. Pharmacologic effects were expressed as the percent change of blood cholesterol level. Cost estimates included patients' travel expenses and time loss as well as resource consumption in the health care sector. Bezafibrate was the most efficient agent for reducing total cholesterol levels, having an cost over 1 year of ￦31.400 per percent reduction in total cholesterol. Simvastatin (10mg/d) was also efficient(￦33,100 per percent reduction). Chole styramine(8g/d) was least efficient at ￦90,200. For low-density lipoprotein cholesterol. simvastatin(10mg/d) was most efficient, at ￦23,200 per percent reduction, followed by lovastatin(20mg/d) at ￦28,000. Gemfibrozil was least efficient at ￦77,800 per percent reduction. For high-density lipoprotein cholesterol. bezafibrate(400mg/d) was most efficient at ￦39,300 per percent increase of high-density lipoprotein cholesterol. Cholestyramine was least efficient at ￦514,700. Analyses combining low-density lipoprotein cholesterol and high-density cholesterol effects suggest that bezafibrate(600mg/d) and simvastatin (10mg/d) were most efficient for reducing cardiovascular risk. The cost-effectiveness analysis results show that both simvastatin and bezafibrate could be efficient treatment. Simvastatin provide more effective treatment at higher cost, whereas bezafibrate is more cost-effective, as it may be less effective, at lower cost. Therefore, clinicians should choose reasonable treatment according to the patient's needs This pharmacoeconimc analysis will provide a guideline for efficient pharmacologic treatment and also be reference data for pricing new drugs.